Table 5.
Vaccines Efficacy and effectiveness against Variants of Concern.
| Vaccine Name | Non-Variant and Variants of Concern | |||||
|---|---|---|---|---|---|---|
| Non-Variant | B.1.1.7 (Alpha) | B.1.351 (Beta) | P.1 (Gamma) | B.1.617.2 (Delta) |
||
|
Pfizer
Comirnaty (BNT162b2) |
Overall efficacy: | 95% [165,166] | 90–93% 90% [167] Similar to non-variant [118,121] |
75% [165] | No evidence of reduced protection | 75–82% [139] Single dose: ~88% [168] |
| Asymptomatic disease: | N/A | Israel: 90.7–92.2% [159] | N/A | N/A | N/A | |
| Symptomatic disease: | Trial: 89–93.2% Israel CLALIT: 87–98% [169] England (80 + years): 85–93% [170] |
Israel: 96.7–97.2% Canada: 89% [159] |
Canada: 84% two doses [159] | Canada: 84% two doses [159] | Single dose: 33% Two doses: 88% [139] ~88% [164] Canada: 87% [159] |
|
| Severe disease: | UK Siren: 95.3–100% [171] Israel CLALIT:75–100% [169] England (80 + years): 37–62% lower risk of mortality 80 + years [172] Israel (85 + years): 97% 7 days after 2nd-dose decreased mortality [173] |
Qatar: 81.7–100% [165] | Qatar: 92.2–99.5% [165] | N/A | ||
| Reduced hospitalization: | England (80 + years): 33–52% in 80 + years [172] Israel (85 + years): 96.9% in 85 + years [173] |
Canada: 95% [159] | Canada: 95% (two doses) [159] | Canada: 95% (two doses) [159] | Single dose: 46–99% Two doses: 86–99% [164] Scotland: 92% [140] Canada: 78% (single dose) [159] |
|
| Decreased infection: | UK Siren: 76–97% [171] Israel CLALIT: 88–95% [169] Israel: 94.1% in 85 + years [173] |
Qatar: 85.9–92.3% [165] | Qatar: 70.5–78.9% [165] | N/A | ||
|
Moderna COVID-19 vaccine
(mRNA 1273) |
Overall efficacy: | 94.1% [174] 89.3–96.8% [174] >90% [175] >65 years: 61.4–95.2% Adolescents: 100% [176] |
N/A | 6.5-fold reduction in neutralizing antibodies in laboratory study [160] | 2.6-fold reduction in neutralizing antibodies in laboratory study [160] | |
| Asymptomatic disease: | Single dose: 80% after 14 days Two doses: 90% after 14 days [125] |
N/A | N/A | N/A | N/A | |
| Symptomatic disease: | 89.3–96.8% (Trial) Single dose: 80% after 14 days Two doses: 90% after 14 days [177] |
Canada: 92% [159] | Canada: One dose 77% [159] | Canada: One dose 77% [159] | Canada: One dose 72% [159] | |
| Severe disease: | 100% [174] >95% [175] |
N/A | N/A | N/A | N/A | |
| Reduced hospitalization: | N/A | Canada: 94% (two doses) [159] | Canada: 89% (single dose) [159] | Canada: 89% (single dose) [159] | Canada: 96% (single dose) [159] | |
|
AstraZeneca/Oxford
COVID-19 Vaccine AstraZeneca (AZD1222); |
Overall efficacy: | 55–81% [178] 58–95% in 65 + years (US Study) 27–90% after 35 + days in 70 + years [172] 60–81% in 80 + years [170] |
~75% [107,178] | ≤10% [130] | Antibody titers reduced by 2.9-fold [179] 40.7–69.7% (Trial, non-variant specific) |
53–66% [140] Single dose: 60–71% [164] |
| Symptomatic disease: | 70.7–91.4% [107] 68–82% [180] 55–81% [178] |
43.6–84.5% [107,181] Two doses: 66% [172] |
-76.8–54.8% [130] Canada: One dose 48% [159] |
Canada: One dose 48% [159] | Single dose: 33% Two doses: 60% [139] ~67% [164] Canada: One dose 67% [159] |
|
| Severe disease: | 100% [180] | N/A | N/A | |||
| Reduced hospitalization: | 100% [180] 60–81% in >80years [170] 74–89% in 70–79 years [170] |
Canada: Single dose 85% prevention [159] | Canada: Single dose 83% prevention [159] | Canada: Single dose 83% prevention [159] | Single dose: 51–83% Two doses: 75–97% [164] 92% [182] Scotland: 73 [140] Canada: 88% (single dose) [159] |
|
| Decreased infection: | 42–60.1% [107] Single dose: 60–70% [183] |
N/A | N/A | N/A | N/A | |
|
Johnson and Johnson Ad26. CoV2-S |
Overall efficacy: | 66% [184] | 30.3–95.3% [185] 70% [133] |
72% (USA) 66% (Latin America) 57% (South Africa) [133] |
68% [133] | 60% [185] |
| Symptomatic disease: | 58.2–81.7% [133] Moderate-severe: 59–73.4% [133] |
N/A | 41.2–78.7% [132] | 48.8–80.7% [132] | ||
| Severe disease: | 9.4–99.7% [133] Severe-critical: 54.6–89.1% [133] 85.4% [184] |
N/A | 46.2–95.4% [133] | 7.8–99.7% [133] | N/A | |
|
Novavax NVX-CoV2373 |
Overall efficacy: | 89% [186] | ~85.6% [187] ~86% [187,188] |
~49% [186] 60% [187] |
No evidence yet | No evidence yet |
| Symptomatic disease: | 73.8–99.5% [188] 100% against severe disease and hospitalization [187,189] |
71.3–93.5% [188] | 28.4–63.1% [133] 6.1–72.8% [137] 60% [137] |
|||
|
Sputnik V (also known as Gam- Covid-Vac) |
Overall efficacy: | ~91% [137] | No evidence yet | No evidence yet | ||
| Symptomatic disease: | 85.6–95.2% [190] | No evidence yet | No evidence yet | |||
| Severe disease: | 94.4–100% [191] | |||||